CLEVELAND, May 8, 2024
/PRNewswire/ -- NeuroTherapia, an early-stage clinical
pharmaceutical company, announced today that it has received a
grant from the Alzheimer's Association Part the Cloud program for
the development of its first-in-class drug, NTRX-07, for the
treatment of Alzheimer's disease (AD).
The grant from the Alzheimer's Association will help fund the
clinical development of NTRX-07, which has shown promising results
in preclinical studies and in a small cohort of AD subjects in a
Phase 1 study for the treatment of Alzheimer's disease. NTRX-07 is
a novel drug that targets neuroinflammation, a key driver of
Alzheimer's disease, and has the potential to slow or even halt the
progression of the disease.
"We're thrilled to receive this grant from Part the Cloud and to
have their support in the development of NTRX-07," said
Tony Giordano, CEO of NeuroTherapia.
"Alzheimer's disease is a devastating illness that affects millions
of people worldwide, and we're committed to developing innovative
treatments that can make a real difference in the lives of patients
and their families."
"NTRX-07 represents a new approach to the treatment of AD by
addressing the neuroinflammation that plays a role in the damage to
the brain. It is an orally administered drug, showing a good safety
profile at doses predicted to be efficacious based on modeling of
the animal data in the recently completed Phase 1 safety studies in
healthy volunteers and a small group of patients with Alzheimer's
disease," said Joseph Foss, M.D.,
Chief Medical Officer for NeuroTherapia. "This Phase 2a study will
expand our understanding of the drug in patients with Alzheimer's
Disease and may provide early insights into its effects."
"Treatments that target Alzheimer's from all angles and all
stages of the disease are essential, and that's why strategic
research funding that works to diversify the drug pipeline is so
important," said Heather Snyder,
Ph.D., Alzheimer's Association vice president of medical and
scientific relations. "The Alzheimer's Association through Part the
Cloud is thrilled to support promising early stage clinical trials,
such as this one, by helping accelerate the transition of findings
from the laboratory into possible treatments."
This is the second grant for the development of NTRX-07 from the
Alzheimer's Association. NeuroTherapia has also received venture
funding from the Alzheimer's Drug Discovery Foundation, Cleveland
Clinic, Brain Trust Accelerator Fund II and Dolby Family Ventures
that allowed the Company to complete Phase 1 clinical trials and
position itself for the upcoming Phase 2a trial, which is designed
not only to show safety and tolerability but also to give an
indication of biological activity.
For more information about NeuroTherapia and the development of
NTRX-07, please visit www.neurotherapia.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurotherapia-receives-grant-from-alzheimers-association-for-development-of-first-in-class-drug-for-alzheimers-disease-302139707.html
SOURCE NeuroTherapia, Inc.